Comparison · NCT02731131-e9463f6a
Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: Number of Participants With Negative HDV RNA at End of Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: Number of Participants With Negative HDV RNA at End of Treatment. Trial comparisons, record NCT02731131-e9463f6a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02731131-e9463f6a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0301 | 0.564 | wilson | |
| Risk in group 2 | 0.333 | 0.0968 | 0.7 | wilson | |
| Risk difference, group 1 minus group 2 | -0.167 | -0.558 | 0.295 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.5 | 0.0602 | 4.15 | log | |
| Odds ratio, group 1 over group 2 | 0.4 | 0.0259 | 6.18 | log | |
| Number needed to treat, for one fewer participant with the outcome on Group A: Monotherapy With Peginterferon Alfa-2a than on Group B: Combination With Peginterferon Alfa-2a + Ribavirin | 6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A: Monotherapy With Peginterferon Alfa-2a | Participants received peginterferon alfa-2a for 48 weeks as 180 mcg once weekly via SC injection. | 1 | 6 | OG000 |
| Group 2 | Group B: Combination With Peginterferon Alfa-2a + Ribavirin | Participants received peginterferon alfa-2a plus ribavirin for 48 weeks. Peginterferon alfa-2a was given as 180 mcg once weekly via SC injection. Ribavirin was administered as 1000 to 1200 mg per day in divided (morning/evening) oral doses. The specific dose was determined according to the participant's body weight at Baseline. | 2 | 6 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Negative HDV RNA at End of Treatment
- Description
- Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at the end of treatment (Week 48) was reported.
- Time frame
- Week 48
- Population
- ITT Population.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
- NCT number
- NCT02731131
- Phases
- PHASE2
- Conditions
- Hepatitis D, Chronic
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2016-07-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02731131?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02731131-e9463f6a